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Abstract: Sjögren’s syndrome (SS) is characterized by extensive lymphocytic infiltration of the salivary
and lacrimal gland (LG), resulting in acinar cell destruction and organ dysfunction. The underlying
pathogenesis of SS remains largely unknown, and studies historically focus on defining late-stage
disease. Here, we identify tissue programs associated with disease onset using transcriptomic
and immunohistological analysis of LGs from 5- and 7-week-old mice deficient in autoimmune
response element (Aire). At 5 weeks of age (wk), Aire-/- mice show minimal tissue dysfunction
and destruction compared to 7 wk Aire-/-, which exhibit severe dry eye, poor tear secretion,
extensive lymphocytic infiltration, reduced functional innervation, and increased vascularization.
Despite this mild phenotype, 5 wk Aire-/- LGs were highly enriched for signaling pathways
previously associated with SS, including interferon gamma (IFNγ), interleukin 1 beta (IL1β),
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), toll-like receptor (TLR)
signaling, and interleukin-6/signal transducer and activator of transcription 3 (IL6/STAT3) signaling.
Novel signaling pathways such as the semaphorin–plexin pathway were also noted. Intriguingly,
we found an expansion of the ductal network with increasing disease. Activated STAT3, a blocker
of apoptosis, was restricted to the ductal system and also increased with damage, highlighting
its potential as a promoter of ductal cell survival. These data demonstrate the early activation of
signaling pathways regulating inflammation, innervation, and cell survival before the onset of clinical
disease indicators, suggesting their potential value as diagnostic biomarkers.
Keywords: Sjögren’s syndrome; disease progression; pathway activation; Aire mouse
1. Introduction
Sjögren’s syndrome (SS) is a complex autoimmune exocrinopathy that has been extensively
reported in the clinical literature. Although a systemic disorder, it predominately affects the
salivary and lacrimal glands (LG) with lymphocytic infiltration of these tissues resulting in clinical
manifestations that include xerostomia (dry mouth) and keratoconjunctivitis sicca (dry eyes) [1].
While several important discoveries have been made in the clinical diagnosis and management of
SS, many of the molecular pathways that mediate the pathogenesis of SS-associated exocrinopathy
remain poorly articulated. This is due, in part, to a limited understanding of the genetic framework
that underpins the disease process and the lack of meaningful genetic biomarkers that are strongly
associated with the disease. Equally problematic is the lack of progress in defining early markers
Int. J. Mol. Sci. 2018, 19, 3628; doi:10.3390/ijms19113628 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2018, 19, 3628 2 of 18
of disease, with diagnosis being largely dependent on late-stage indicators such as blood testing
for anti-Sjögren’s syndrome-related antigen A (SSA/Ro), Schirmer test for lacrimal function,
and measurements of saliva flow. In many cases, analysis of labial salivary gland biopsies takes
place well after the disease has been initiated and extra-glandular organ involvement has already
occurred, thereby limiting treatment options for SS patients.
Although some progress has been made in the phenotypic and genomic characterization of SS,
including a recent genome-wide association study [2,3], causative factors remain elusive. Analyses
of patient biopsies and mouse models of SS have identified a large number of immune signaling
pathways that may underlie the disease, such as activation of IFNγ producing T-helper 1 (Th-1) [4,5]
and IL17 producing T-helper 17 (Th-17) CD4+ T cells [6,7], B cell activation [8,9], upregulation of
pro-inflammatory cytokines (e.g., IL1, IL6, and IL17) [6,7,10,11], ligation of Toll-like receptors expressed
on infiltrating immune and ductal epithelial cells [12,13], phosphorylation of signal transducer and
activator of transcriptions (STATs) [13], and signaling via the NF-κB pathway [13]. Also notable is the
discovery of a link between the nervous and immune system mediated by neuroimmune semaphorins
(e.g., Sema4A, 4D, 6D, and 7A). While originally identified for their signaling role in axon guidance
through direct binding of plexin receptors, more recently, semaphorins have been shown to provide
finetuning of inflammatory processes that are altered in autoimmune diseases, making them interesting
molecules for immunotherapy [14–16].
To gain a better understanding of global gene expression and how it is altered in the early stages
of SS exocrinopathy, we used a well-characterized, spontaneous mouse model of SS and state-of-the-art
genetic screening methods to conduct an unbiased exploration of global gene expression. In comparison
to the majority of SS mouse models, mice deficient in autoimmune regulator gene (Aire) exhibit classic
signs of aqueous-deficient dry eye in a swift fashion, allowing for an understanding of disease processes
in the absence of the effects of aging. By 7–8 weeks the lacrimal glands of Aire-/- mice exhibit extensive
lymphocytic infiltration combined with corneal pathologies and severe dry eye. However, it is not
known when these disease outcomes are initiated in the Aire-/- mouse. Aire-/- mice on the BALB/c
background were selected over Aire-/- mice on the NOD background for this study due to their
less rapid development of severe disease. NOD. Aire-/- mice develop multi-organ autoimmune
disease that results in an average life span of ~8 weeks. In contrast, BALB/c. Aire-/- mice develop
SS-associated dry eye and exocrinopathy that is nearly identical in appearance to NOD. Aire-/-, but the
time course of disease development is slower, the extent of multi-organ involvement is less, and the
average life span extends up to ~16 weeks. These characteristics make BALB/c. Aire-/- mice an ideal
model for studies of disease progression.
Here, we used RNA sequencing (RNAseq), the gold standard for generating quantitative
estimates of RNA abundance and disease-specific alterations in gene expression, to examine the entire
transcriptome of CD4+-T-cell-mediated exocrinopathy in 5-week-old (wk) Aire-/- mice. While dry eye
researchers have used RNAseq technology to explore the transcriptome of ocular tissues, none have
focused on the specific alterations in SS-associated exocrinopathy during the early stages of disease or
gone on to validate differences in gene expression using traditional readouts, such as qPCR or protein
expression (e.g., immunohistochemistry or Western blot). Our findings provide a holistic overview of
genetic changes associated with early disease processes, as well as specific genetic biomarkers that can
be used to define the mechanism of disease development and progression.
2. Results
2.1. Aire-/- at 5 Weeks of Age Exhibit Mild Lacrimal Gland Disease Compared to Mice at 7 Weeks
In order to begin to define pathways activated during early disease onset we utilized the Aire-/-
mice which exhibit epithelial barrier disruption, poor tear secretion, extensive lymphocytic infiltration,
and vascularization of both lacrimal glands and cornea, as well as severe corneal pathologies and loss
of lacrimal acini by 8 weeks of age (wk) as compared to age-matched wild types (WT) (Figure 1) [17].
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To determine when these outcomes are initiated, we measured lissamine green staining (indicator
of epithelial barrier function) and stimulated tear production in Aire-/- and WT mice at 5 and 7 wk.
Although lissamine green staining was increased in both the 5 and 7 wk Aire-/- cornea, this difference
was greatly pronounced in 7 wk tissue, indicating extensive damage by this time point (5 wk: 1.00 ±
0.15 vs. 2.71 ± 0.26, p = 0.0013; 7 wk: 1.00 ± 0.37 vs. 8.13 ± 0.30, p < 0.0001, Figure 1A). Consistent with
the lissamine green outcomes, stimulated tear production was markedly decreased in 7 wk Aire-/-,
whereas tear levels were similar to WT in 5 wk Aire-/- animals (5 wk: 1.00 ± 0.094 vs. 0.75 ± 0.19,
p = 0.34; 7 wk: 1.00 ± 0.055 vs. 0.20 ± 0.065, p < 0.001, Figure 1A, right). As these results suggested
mild disease at 5 wk and severe disease at 7 wk, we then characterized inflammation of the 5 and 7 wk
Aire-/- lacrimal gland and cornea. As expected, we measured extensive CD4+ T cell inflammation
of the cornea in 7 wk Aire-/- tissue, with CD4+ T cells infiltrating the cornea (0.0 ± 0.0 vs. 8.66 ±
2.99, p = 0.03, Figure 1B), while both CD4+ T cells (0.0 ± 0.0 vs. 25.60% ± 5.04, p = 0.002, Figure 1C)
and CD45R+ B cells densely infiltrated throughout the lacrimal gland (0.0 ± 0.0 vs. 30.05% ± 6.02,
p = 0.004, Figure 1D). In contrast, at 5 wk there were few to no immune cells in the cornea (0.0 ± 0.0 vs.
1.17 ± 0.83, p = 0.22, Figure 1B) and fewer and more restricted foci of T (0.0 ± 0.0 vs. 6.42% ± 0.58,
p < 0.0001, Figure 1C) and B cells (0.0 ± 0.0 vs. 6.11% ± 1.21, p = 0.015, Figure 1D) in 5 wk Aire-/-
lacrimal glands. We previously found an increased number of dilated blood vessels within the intact
epithelial region during disease progression (5 wk: 0.50 ± 0.50 vs. 3.40 ± 1.21, p = 0.07; 7 wk: 1.00 ±
0.71 vs. 2.00 ± 0.55, p = 0.31 Figure 1E), consistent with chronic inflammation; however, there was
no statistically significant difference in vessel diameter between 5 and 7 wk Aire-/- lacrimal glands
compared to age-matched wild-type mice (3.40 ± 1.21 vs. 2.00 ± 0.55, p = 0.33, Figure 1E, right).
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Figure 1. Disease progression in the Aire-/- mouse as shown by (A) increased lissamine green staining 
of the cornea and reduced tear secretion, (B) extensive CD4+ T cell infiltration of the cornea, (C) 
expansion of CD4+ T cell- and (D) CD45R+ B cell-containing foci in the lacrimal gland, and (E) altered 
tissue structure and blood vessel dilation in the lacrimal gland indicated by collagen type IV/ platelet 
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Figure 1. Disease progression in the Aire-/- mouse as shown by (A) increased lissamine green
staining of the cornea and reduced tear secretion, (B) extensive CD4+ T cell infiltration of the cornea,
(C) expansion of CD4+ T cell- and (D) CD45R+ B cell-containing foci in the lacrimal gland, and (E)
altered tissue structure and blood vessel dilation in the lacrimal gl nd indicated by collagen type IV/
platelet and endothelial cell adhesion molecule (COLIV/PECAM) staining. Data are expressed as
mean ± SEM. n = minimum of 4 mice per group, and each sample is represented by a circle, square,
or triangle within a group. Changes in Lissamine green and tear secretion are expressed as fold change
relative to average WT. Controls in (B–D) included 5-week-old (wk) and 7 wk WT as the WT at both
ages did not show any CD4+ T cell or CD45R+ B cell infiltration. * p < 0.05, ** p < 0.01, *** p < 0.001.
Scale bar = 100 µm.
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2.2. Gene Expression Analysis Reveals Multiple Signaling Pathways Upregulated in the Lacrimal Glands of
Mice Exhibiting Mild Disease
Current studies have pointed to a number of specific pathways being active in late stage disease,
yet whether these are also present at early stages is unclear. To address this issue, we compared
gene expression in lacrimal glands from 5 wk Aire-/- with very mild disease, i.e., those with
lymphocytic infiltrates ≤10% (Figure 1C) to their age-matched wild-type controls via bulk RNA
sequencing (Tables S1 and S2). As shown in Figure 2A, principal component analysis of LG
samples revealed transcriptomes clustered as discrete groups based on their genotype, with some
variability within groups. Our differential expression analysis demonstrated extensive changes in gene
expression, with an overall increase in global expression as shown by 1909 genes being upregulated
(>2-fold; p < 0.01) compared to 694 being downregulated (<−2; p < 0.01; Figure 2B). Not surprisingly,
gene ontology analysis indicated a significant enrichment in genes associated with the adaptive
and innate immune responses (Figure 2C, Table A1). These include genes involved in T and B cell
activation and proliferation, chemotaxis, antigen presentation and processing (MHC1), macrophage
activation and phagocytosis, regulation of T-helper cells (type 1), mast cell and neutrophil activation,
and cytokine production and signaling (for a list of representative genes, see Table 1; for complete
list of genes, see Table S3). In line with our immunostaining for inflammation and blood vessels,
we identified upregulation of gene sets involved in hematopoiesis and lymphoid organ development,
indicating the creation of germinal centers as well as vascularization. Interestingly, we also found an
enrichment for actin cytoskeleton genes, suggesting that the tissue was remodeling. Our unbiased
analysis also revealed a significant enrichment of numerous inflammatory signaling pathways that
have been reported to occur in the advanced-stage human disease as well as in a number of SS mouse
models (including the Aire-/-). These include IFNγ [18,19], NF-κB [13], toll-like receptor signaling [12],
interleukin (e.g., IL1β, IL2, IL6), and JAK/STAT [13] (see Table 1 for representative genes). In addition
to these pathways, we also found a small but significant downregulation of secretory genes including
Pip (Fold change (FC) = −2.3, p = 0.00032), secretoglobulins (e.g., Scgb1b3, FC = −3.57, p = 0.0002),
and exocrine gland secreted peptides (e.g., Esp6, FC =−2.9, p = 0.0058), as well as the acinar marker and
master regulator of secretion Basic Helix-Loop-Helix Family Member A15 (Bhlha15/Mist1; FC = −2.04,
p = 0.0078); this suggests that, despite tear secretion being similar to in wild-type mice, LG function
was being reduced. Concurrent with the loss of acinar genes was an upregulation of the ductal markers
mast/stem cell growth factor receptor (Kit; FC = 2.5, p < 0.00005) and solute carrier 12 member 4
(Slc12a4/KCC1; FC = 2.2, p < 0.005). These results suggest that remodeling of the secretory tissue and
alterations in the proportion of acinar and duct cells in LG begins at or before 5 weeks.
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Figure 2. RNA sequencing (RNAseq) of the 5 wk Aire-/- lacrimal glands revealed genes significantly
altered during early disease, implying that these genes could serve as early disease markers. (A) The
Principal Component Analysis (PCA) plot shows clusters of samples. (B) The volcano plot shows
number and magnitude of genes significantly up- and down-regulated (above and below; FC = 2,
respectively) during early disease. (C) Ranked list of biological pathways enriched during the early
stages of disease.
Table 1. List of representative genes that are significantly altered in the Aire-/- lacrimal gland during
early disease onset from RNAseq showing fold change and p-value compared to wild type.
Cell/Process Gene Symbol Gene Description Fold Change(-/- vs. WT)
p-Value
(-/- vs. WT)
Immune cell
Adaptive
Cd79b B-cell antigen receptor complex-associated protein β chain 200.00 5.35 × 10−3
Cd19 B-lymphocyte antigen CD19 172.92 3.30 × 10−7
Cd3d T-cell surface glycoprotein CD3 δ chain 106.92 8.57 × 10−3
Cd3g T-cell surface glycoprotein CD3, gamma polypeptide 100.81 9.69 × 10−3
Lat linker for activation of T cells 42.93 1.76 × 10−6
Innate
Srgn Serglycin (mast cell) 5.70 4.65 × 10−6
Ncf1 n utrophil cytosolic factor 1 12.36 1.67 × 10−5
Klrk1 killer cell lectin-like recept r subfamily K, member 1 32.18 1.23 × 10−6
Cd68 CD68 antigen 3.65 1.95 × 10−5
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Table 1. Cont.
Cell/Process Gene Symbol Gene Description Fold Change(-/- vs. WT)
p-Value
(-/- vs. WT)
Vascular
Vegfd vascular endothelial growth factor D 3.70 1.03 × 10−3
Pecam1 platelet/endothelial cell adhesion molecule 1 2.67 4.3 × 10-4
Vcam1 vascular cell adhesion molecule 1 23.10 5.68 × 10−8
Proliferation
Aurkb aurora kinase B 20.12 1.26 × 10−5
Top2a topoisomerase (DNA) II α 3.69 3.17 × 10−4
Tpx2 Microtubule Nucleation Factor, microtubule-associated 11.59 2.28 × 10−5
Cell death
Bid BH3 interacting domain death agonist 9.69 6.13 × 10−6
Casp3 caspase 3 3.73 7.69 × 10−5
Trp53 transformation related protein 53 2.30 2.60 × 10−3
Cell migration
Cxcl9 chemokine (C–X–C motif) ligand 9 167.93 6.30 × 10−3
Cxcr3 chemokine (C–X–C motif) receptor 3 43.23 1.34 × 10−7
Csf1r colony stimulating factor 1 receptor 3.25 1.30 × 10−4
Sell selectin, lymphocyte 223.19 4.79 × 10−3
Axon guidance/
immunoregulation
Sema4a
sema domain, immunoglobulin domain (Ig),
transmembrane domain (TM) and short cytoplasmic
domain, (semaphorin) 4A(Sema4a)
2.42 9.17 × 10−4
Sema4c
sema domain, immunoglobulin domain (Ig),
transmembrane domain (TM) and short cytoplasmic
domain, (semaphorin) 4C(Sema4c)
4.12 3.72 × 10−4
Sema4d
sema domain, immunoglobulin domain (Ig),
transmembrane domain (TM) and short cytoplasmic
domain, (semaphorin) 4D(Sema4d)
2.35 2.03 × 10−4
Sema6d sema domain, transmembrane domain (TM), andcytoplasmic domain, (semaphorin) 6D 3.56 9.57 × 10
−4
Sema7a sema domain, immunoglobulin domain (Ig), and GPImembrane anchor, (semaphorin) 7A 3.02 2.62 × 10
−4
Plxnb1 plexin B1 4.78 2.33 × 10−6
Plxnd1 plexin D1 3.12 2.72 × 10−4
Secretion
Scgb1b19 secretoglobin, family 1B, member 19 −4.61 3.33 × 10−3
Pnliprp1 pancreatic lipase related protein 1 −4.08 8.44 × 10−3
Scgb1b3 secretoglobin, family 1B, member 3 −3.57 2.24 × 10−4
Scgb1b20 secretoglobin, family 1B, member 20 −3.09 7.62 × 10−5
Pip prolactin induced protein −2.31 3.22 × 10−4
Bhlha15 basic helix–loop–helix family, member a15(Bhlha15) −2.04 7.58 × 10−3
Esp6 exocrine gland secreted peptide 6 −2.39 5.81 × 10−3
Signaling pathways
TNF
Tnfrsf18 tumor necrosis factor receptor superfamily, member 18 33.63 3.64 × 10−6
Tnfrsf13b tumor necrosis factor receptor superfamily, member 13b 27.71 1.09 × 10−6
NF-κB
Nfkbie nuclear factor of kappa light polypeptide gene enhancer in Bcells inhibitor, epsilon 28.23 4.08 × 10
−6
Nfkbiz nuclear factor of kappa light polypeptide gene enhancer in Bcells inhibitor, zeta 2.90 1.29 × 10
−4
Eomes eomesodermin 16.56 4.90 × 10−6
Pim1 proviral integration site 1 6.25 1.17 × 10−5
Toll-like
Tlr2 toll-like receptor 2 10.24 3.30 × 10−6
Tlr6 toll-like receptor 6 5.63 1.17 × 10−3
Tlr7 toll-like receptor 7 14.87 5.74 × 10−6
Tlr13 toll-like receptor 13 13.19 2.39 × 10−4
JAK/STAT
Jak2 Janus kinase 2 4.31 2.75 × 10−5
Jak3 Janus kinase 3 25.17 9.18 × 10−6
Stat1 signal transducer and activator of transcription 1 12.07 2.42 × 10−8
Stat2 signal transducer and activator of transcription 2 3.65 1.92 × 10−5
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Table 1. Cont.
Cell/Process Gene Symbol Gene Description Fold Change(-/- vs. WT)
p-Value
(-/- vs. WT)
Interleukin
Il1b interleukin 1β 12.19 3.16 × 10−5
Il2ra interleukin 2 receptor, α chain 9.35 2.49 × 10−4
Il2rg interleukin 2 receptor, γ chain 21.03 3.65 × 10−7
Il6ra interleukin 6 receptor, α 7.40 9.40 × 10−5
Interferon
Igtp interferon gamma induced GTPase 23.07 2.11 ×10−8
Irf1 interferon regulatory factor 1 8.23 2.06 × 10−6
Irf5 interferon regulatory factor 5 11.99 4.43 × 10−6
2.3. Validation of Gene Expression Data Confirms the Presence of Multiple Inflammatory Pathways Apparent at
Early Stages of Disease Development
To validate the alterations in gene expression/pathways/processes measured via transcriptomic
analysis, as well as to define their spatiotemporal distribution and abundance with increasing disease,
we performed a combination of Western blot and immunofluorescence in 5 and 7 wk Aire-/- and
WT LG. Immunofluorescent analysis confirmed the reduction in the acinar cell compartment and
acquisition of a more ductal phenotype during disease progression (Figure 3A, top and middle panels),
with the accumulation of KIT+ sodium potassium calcium co-transporter 1 (NKCC1)+ ductal tissue in
the Aire-/- (Figure 3A) and the reduction in MIST1+ acini (5 wk: 4.63 ± 0.69 vs. 1.44 ± 0.14, p = 0.02;
7 wk: 4.64 ± 0.86 vs. 0.70 ± 0.09, p = 0.02, Figure 3B). Surprisingly, we found MIST1 to be co-expressed
in NKCC1+ cells in Aire-/- LG at 7 wk (Figure 3B, arrowheads). Closer analysis at 5 wk showed
only a few of these co-expressing cells, suggesting either that ductal cells are transdifferentiating
towards the acinar lineage or that acinar cells begin to express ductal markers. To determine if the
proportion of duct cells was increasing via proliferation or via loss of acini, we immunostained for
the cell proliferation marker Ki67 and the apoptotic marker cleaved caspase-3 (CC3). We found a
significant increase in duct cell proliferation (5 wk: 0.98% ± 0.60 vs. 6.12% ± 1.59, p = 0.04; 7 wk:
0.33% ± 0.33 vs. 9.90% ± 2.33, p = 0.02, Figure 3C) and limited cell death (5 wk: 0.11% ± 0.11 vs.
0.31% ± 0.14, p = 0.28; 7 wk: 0.19% ± 0.11 vs. 0.92% ± 0.16, p = 0.01, Figure 3D) in both the 5 and
7 wk LG compared to WT LG. In contrast to this finding, acinar cells showed little proliferation and
extensive apoptosis at both ages (5 wk: 0.25% ± 0.14 vs. 4.50% ± 0.52, p < 0.001; 7 wk: 0.50% ± 0.20 vs.
4.41% ± 1.23, p = 0.03, Figure 3D), confirming our previous findings at 8 wk that the acini but not the
ducts are adversely impacted by chronic inflammation in the Aire-/- mouse model.
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immunostaining of WT tissue for pSTAT3 showed extensive phosphorylated (active) protein within 
ductal cells but not in acinar cells. Furthermore, in the 5 wk Aire-/- LG we found increased numbers 
Figure 3. Str ctural changes in the Aire-/- lacrimal gland. ( ) I presence of ductal cell markers
NKCC1 and KIT expression. (B) Gradual loss of Mi t1+ ac nar cells with expansion of NKCC1+ cells.
Arrowheads indicat MIST1+ cinar cells co-expressing ductal marker NKCC1. (C) Increased ductal cell
proliferation and (D–E) incre se apoptotic acinar cells in Aire-/- lacrimal gland. Data are expressed
as m an ± SEM. Dat in A are expressed as ratio of MIST- o NKCC1-positive cells. Data in (B–E) are
expressed as percentage of proliferating o apoptotic cells. n = 3–4 mice per group, and each sample is
repre ented by a ci cle, square, or triangle within a group. * p < 0.05, ** p < 0.01. Scale bar = 1 0 µm.
Given the overrepresentation of the janus kinase/signal transducers and activators of transcription
(JAK/STAT) pathways i the Aire-/- LG at 5 wk (Figure 2C) an the involvement f the STAT
pathway in promoting cell surv val, we n xt asked whether duct cell survival was due increased
phosp oSTAT3 (pSTAT3), a potent inhibitor of cell apoptosis. Unexpectedly, immunostaining of WT
tis ue for pSTAT3 showed extensive phosphorylated (active) protein within ductal cells but not in
acinar cells. Furthermore, in the 5 wk Aire-/- LG we found increased numbers of pSTAT3+ immune
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cells (Figure 4A), as well as pSTAT3+ ductal cells (5.63 ± 1.80 vs. 35.75 ± 7.29, p = 0.02, Figure 4B).
The number of pSTAT3+ ductal cells was similar at 5 and 7 wk (35.75 ± 7.29 vs. 46.6 ± 6.35, p = 0.3,
Figure 4B), confirming the activation of the JAK/STAT signaling pathway early in the disease process
and likely mediated by infiltrating immune cells. Although we also observed an increase in Il6 receptor
(Il6ra) transcripts (FC = 7.40, p < 0.0001, Table 1) and IL6Ra protein at 5 wk (0.97 ± 0.03 vs. 6.97 ± 1.99,
p < 0.05, Figure 4B), a well-known activator of STAT3, immunostaining revealed an enrichment of
the receptor in immune cells but not in ductal cells, indicating that another factor was promoting the
phosphorylation of STAT3 in these cells. In addition, Stat1 was also significantly upregulated during
early disease (FC = 12.07, p < 0.00005, Table 1) and in line with elevated STAT1 protein level by Western
blot (5 wk: 0.94 ± 0.19 vs. 6.58 ± 1.10, p = 0.01; 7 wk: 0.89 ± 0.07 vs. 3.65 ± 0.55, p = 0.01, Figure 4C).
STAT1 is known to be activated by signaling from INFs, and advanced studies on the development of
JAK/STAT inhibitors have found that expression of the STAT1 pathway confers cellular resistance to
DNA-damaging agents and supports tumor growth [20]. Together these data suggest that ducts may
evade cell death through activation of the STAT3 pathway.
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2.4. Denervation of the LG Begins at Early Disease Stages
The GO analysis revealed an increase in the semaphorin–plexin signaling pathway, a pathway
not previously associated with SS that regulates both motility and differentiation of the immune and
nervous systems. In support of this increase, we found increases in transcripts for Sema4c (FC = 4.12,
p = 3.72 × 10−4), Sema4d (FC = 2.35, p = 2.03 × 10−4), Sema6d (FC = 3.56, p = 9.57 × 10−4), and their
receptors Plxnb1 (FC = 4.78, p = 2.33 × 10−6) and PlxnD1 (FC = 3.12, p = 2.72 × 10−4; Table 1). At 5 wk,
Sema7a transcripts (FC = 3.02, p = 0.00026, Table 1) were upregulated despite no change in total
SEMA7A protein (5 wk: 1.16 ± 0.08 vs. 1.25 ± 0.18, p = 0.68). However, by 7 wk, Western blot showed
upregulation of glycosylated (100 kDa), nonglycoslyated (75 kDa), and cleaved forms (50 kDa) during
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disease progression (7 wk: 1.09± 0.05 vs. 2.22± 0.19, p = 0.02, Figure 5A). As this pathway serves roles
in both immune cell trafficking and axon guidance, we questioned whether innervation was different
in the 5 wk Aire-/- compared to WT and 7 wk Aire-/-. As shown in Figure 5B, the extent of β3-tubulin
(TUBB3)+ nerve fibers innervating the 5 wk tissue was reduced compared to WT LG and was similar
to the 7 wk (WT 0.07 ± 0.01 vs. 5 wk 0.03 ± 0.004, p = 0.03, 7 wk: 0.02 ± 0/008, p = 0.01, Figure 5B).
Despite clear depletion of axons in the Aire-/- LG by 5 wk, we found no significant reduction in
acetylcholine production (Figure 5C), as measured via acetylcholinesterase assay (5 wk: 0.0098 ± 0.002
vs. 0.0068 ± 0.008, p = 0.20), suggesting that the remaining nerves showed a compensatory increase in
function at the early disease stages to maintain tear secretion. However, with disease progression and
further destruction of LG tissue, acetylcholine production was significantly reduced in 7 wk Aire-/-
mice (7 wk: 0.019 ± 0.003 vs. 0.005 ± 0.001, p = 0.01, Figure 5C).
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at 5 wk but revealed upregulation of SEMA7A and increased levels of cleaved SEMA7A at 50 kDa at
7 wk. (B) A significant reduction in LG in ervation was observed during early disease. (C) However,
nerve function measured by acetylcholine esterase (AChE) assay was not altered until late disease.
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3. Discussion
Here, we reveal that in the earliest stages of autoimmune exocrinopathy, before functional
output is compromised and corneal pathologies are visible, the lacrimal gland undergoes multiple
phenotypic and molecular alterations associated with late-stage disease. These include tissue
remodeling, such as the progressive loss of acinar cells, expansion of the ductal system, increased
vascularization, and reduced innervation of the secretory epithelium. Phenotypic changes were
accompanied by the enrichment of inflammatory mediators, such as IFNγ, IL1β, IL6, NF-κB, toll-like
receptor, and JAK/STAT signaling pathways; as well as positive regulation of cell proliferation,
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lymphocyte differentiation, B and T cell activation, and pro-inflammatory macrophage expansion.
In addition to confirming the presence of signaling pathways previously associated with late-stage
disease in SS, we also revealed the presence of a novel signaling pathway, the semaphorin/plexin
pathway, that is upregulated in the early stages of disease and may contribute to disease progression.
Taken together, our data suggest that signaling pathways observed in the late stages of SS exocrinopathy
are activated early during disease development and include a combination of pathways regulating
inflammation, innervation, and cell survival.
Loss of corneal integrity and corneal inflammation as a result of reduced tear production is
one of the major hallmarks of patients with SS [21]. Yet, whether loss of epithelial barrier function
and increased corneal inflammation are direct readouts of lacrimal gland damage and dysfunction
remains unclear. We found T and B cell infiltration and activation, pro-inflammatory macrophage
expansion, and activation of multiple inflammatory pathways during disease development when only
mild changes in the corneal epithelium were apparent (as noted by limited lissamine green staining)
and before the acquisition of corneal inflammation or reduced tear secretion. Such an outcome has
important implications for the early detection and diagnosis of dry eye disease. Indeed, our data
suggest that diagnostic tests for aqueous-deficient dry eye are unlikely to identify patients until well
after inflammatory events have been initiated, further increasing the need for early biomarkers of
disease development.
Peripheral innervation is known to be essential to salivary gland homeostasis through the
maintenance and activation of stem cells [22]. Although this specific role has not been evaluated
in the LG, similar to the salivary gland, previous studies have shown that atrophy of LG acini occurs
in the absence of a nerve supply [23]. We previously demonstrated that peripheral innervation is
profoundly reduced in the Aire-/- cornea and lacrimal gland at 8 wk [24], an outcome that is consistent
with reduced innervation observed in the human cornea [25,26]. Intriguingly, in the current study
we unexpectedly found that acetylcholine synthesis was similar between WT and Aire-/- LG at 5 wk
even though the number of nerve fibers within the Aire-/- LG at this age was reduced. This finding
suggests that innervating nerves have compensatory function under conditions of mild inflammation
that preserve tissue architecture as well as tear production. However, as the tissue becomes chronically
inflamed, innervation is lost, resulting in organ dysfunction and tissue degeneration. Although the
specific mechanisms behind the reduction in innervation are not known, one likely player is the
destruction of secretory tissue. Epithelial cells synthesize neurotrophic factors such as GDNF and
neurturin that serve to promote and maintain the nerve supply [27–29]. Although we did not find
these molecules to be altered transcriptionally, whether these proteins are functional within highly
inflamed tissue remains to be determined.
Sjögren’s Syndrome has long been considered a Th1-mediated disease elicited through the
transformation of naïve CD4+ T cells into Th1 lymphocytes. Using the Aire-deficient mouse model,
we have previously shown that IFNγ-secreting CD4 T cells cooperate with local IL1/IL1-receptor
signaling pathways to induce aqueous tear deficiency and ocular surface disease [10,30]. In support
of a Th1 response, our transcriptomic data in the 5 wk Aire-/- LG also identified the enrichment
of Th1 cytokine signaling pathways and factors including IFNγ and TNFα. In addition, we found
a dramatic upregulation of STAT1, a potent promoter of Th1 differentiation and maintainer of Th1
cytokine production [31], which has previously been shown to be overexpressed in salivary glands
of SS patients [32]. Th1 activation and cytokine production occurred in conjunction with increased
expression of CD68, suggesting that exposure of naïve monocytes to IFNγ or TNFα induces M1
(pro-inflammatory) development [33]. Notably, we found that these macrophages also express IL6R
and that tissue showed increased production of its ligand, IL-6, both of which have previously been
correlated with the histological grade of minor salivary gland biopsy [34]. Furthermore, blocking of
IL6R has been shown to ameliorate autoimmune disease in a number of model systems (reviewed
in [35]), suggesting that macrophage expansion may be a key driver of early disease. In support of
this argument, our previous study demonstrated that ablation of macrophages in the Aire-/- led to
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significant improvements in lacrimal gland exocrinopathy and tear secretion [36]. Thus, early targeting
of these cells may aid in reducing the pathogenesis of the condition.
Our data reveals the upregulation of a novel pathway not previously identified in murine models
of SS—the semaphorin–plexin signaling pathway. Semaphorins have traditionally been associated
with the nervous system, being active in the guidance of axons into tissues where they serve as
either repulsive or attractive cues [37]. More recently, numerous semaphorins have been shown to
function in the immune system, gaining the label “neuroimmune regulators”. One key role is serving
as costimulatory molecules for T cell activation, an action that requires the presence of two signals:
the first being TCR/MHC engagement, and the second being B7/CD28 interaction. With proper
co-stimulation, three canonical signaling pathways—NF-κB, AP-1, and NFAT—are activated within
T cells. These pathways lead to the expression of many molecules, such as chemokines, cytokines,
and other cell surface molecules, that promote T cell activation. As such, they serve as a “signal
three” for immune cell activation. In our data we identified significant upregulation of a number of
semaphorins that are either constitutively expressed by T cells such as Sema4d and 6d (FC = 2.3 and 3.56,
respectively, Table 1) or induced upon activation, namely SEMA7A (Table 1 and Figure 5). Upregulation
of cell surface and serum levels of SEMA4D has also been measured in the MRL/lpr mouse model
of SS, an outcome exhibiting a significant correlation with SS autoantibodies. These results suggest
their value as a potential screening tool to monitor disease progression and/or assess the impact of
a therapeutic intervention [16]. Moreover, given their known role in regulating the overall intensity
of immune responses through the “signal three” activation, we predict that these molecules may be
potential therapeutic targets for impairing disease progression.
In summary, our study defines disease progression at both the molecular and phenotypic level
and highlights the need to identify early markers of disease progression. Indeed, our study suggests
that functional outcomes currently being used to confirm disease status, including Schirmer’s test and
lissamine green staining, do not faithfully predict the level of disease apparent within the lacrimal
glands. It is likely that routine testing of tears for inflammatory molecules, such as SEMA4D, STAT1,
TNFα, and IFNγ, may prove to be a more valuable assessment for identifying early disease onset.
Moreover, the extent to which patient discomfort parallels changes in LG pathogenesis remains to
be discerned.
4. Materials and Methods
4.1. Animal Model
Mice were handled in strict accordance with the University of California, San Francisco animal
welfare guidelines for laboratory and animal care. The protocol was approved on 3 May 2018 by the
Institutional Animal Care and Use Committee at the University of California San Francisco (Approval
number: AN174695-01A). Aire-deficient mice on the BALB/c background (BALB/c Aire-/-) were
the gift of Mark Anderson, University of California, San Francisco. Genomic DNA isolated from tail
clippings was genotyped for the Aire mutations by PCR with manufacturer-recommended specific
primers and their optimized PCR protocols. Female mice were used in the study and were between 5
and 7 weeks of age when sacrificed.
4.2. Immunohistological and Immunofluorescence Analysis
To visualize immune cell subtypes, immunohistochemistry was performed with antibodies
specific for CD4 (BD Pharmigen, San Jose, CA, USA) and CD45R (eBiosciences, Waltham, MA,
USA), a donkey anti-rat secondary antibody conjugated to horseradish peroxidase and a DAB
(3,3′-Diaminobenzidine) staining kit. OCT Tissue Tek embedded lacrimal glands and eyes were
sectioned on the cryostat (Leica, Izar, Germany) at 7 µm and mounted on SuperFront Plus slides. To fix
the tissue, sections were incubated with ice-cold acetone at−20 ◦C for 10min and then washed for 5 min
with PBS 3 times. Sections were blocked with 5% normal goat serum for 1hr at RT, and then incubated
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in 3% hydrogen peroxide to inactivate endogenous peroxidases. Primary CD4 (1:50) or CD45R (1:200)
antibodies were prepared in 5% normal goat serum and incubated at 4 ◦C overnight. Sections were
washed for 5 min with PBS 3 times, secondary antibody diluted 1:500 in 5% normal goat serum was
applied for 30 min at room temperature (RT), and then sections were washed again for 5 min with PBS
3 times. Hematoxylin counterstain was utilized to stain the nuclei. For immunofluorescence staining,
OCT Tissue Tek 7 or 20 µm sections were mounted and subsequently fixed with 4% paraformaldehyde
for 20 min at RT, followed by 1 min acetone–methanol, and incubated overnight at 4 ◦C with one or a
combinaton of the following primary antibodies: goat anti-COLIV (1:500, Millipore, Burlington, MA,
USA), rat anti-PECAM (1:300 Millipore), goat anti-NKCC1 (1:300, Santa Cruz Biotech, Dallas, TX, USA),
rabbit anti-cKit (1:200, Cell Signaling, Danvers, MA, USA), rabbit anti-MIST1 (1:1000, gift from Steven
Konieczny), rabbit anti-cleaved Caspase 3 (1:200; Cell Signaling), rat anti-Ki67 (1:100, Dako, Santa Clara,
CA, USA), rabbit anti-TUBB3 (1:500, Covance, Princeton, NJ, USA), rat anti-Ecadherin (1:300, Life
Technologies, Carlsbad, CA, USA), rabbit anti-pStat3 (1:100, Cell Signaling), rat anti-IL6Ra(1:100,
Thermo Fisher), Rat anti-CD68 (1:400, Bio-Rad, Hercules, CA, USA). Antibodies were detected using
Cy2-, Cy3-, or Cy5-conjugated secondary Fab fragment antibodies (Jackson Laboratories, Sacramento,
CA, USA), and nuclei were stained with Hoechst. Fluorescence was analyzed using a Zen Spinning
disk confocal (Jena, Germany), Zeiss Epifluorescence microscope (Thornwood, NY, USA), and NIH
ImageJ software (Bethesda, MD, USA).
CD4+ T cells were quantified in the central corneal region by counting the total number of DAB+
brown cells with an Hemotoxylin & Eosin counterstain associated nucleus. To quantify CD4+ T cells
and CD45R+ B cells in the lacrimal gland, the area of DAB+ signal was measured and divided by the
total area of the lacrimal gland. This value was expressed as a percentage of CD4+ T cell or CD45R+ B
cell infiltration in the tissue.
In the lacrimal gland, MIST1 was utilized to label the acinar population while NKCC1 was utilized
to label the ductal population. Lacrimal glands were imaged by confocal microscopy at a magnification
of 20× with a stack of 20 1 µm slices. To determine the acinar to ductal cell ratio, the total number of
MIST1+ cells associated with Hoeschst-stained nuclei was divided by the total number of NKCC1+
cells associated with Hoeschst-stained nuclei.
Blood vessels were labeled for PECAM and imaged by confocal microscopy at 20× using 1 µm
confocal sections that were combined to produce a 20 µm projection. For assessing blood vessel
dilation, blood vessel area was approximated with an ellipse. The blood vessel diameter was measured
as the length of the approximated width for an approximated ellipse, expressed in micrometers. Blood
vessels with a diameter greater than 6 µm were labeled as dilated. Blood vessel diameter in three 200
µm × 200 µm Ecadherin (ECAD)-positive areas of the tissue was quantified to determine total number
of blood vessels 1–5 µm in diameter and >6 µm in diameter in intact gland.
Twenty-micron lacrimal gland sections were labeled for beta3 tubulin (TUBB3) and ECAD,
and imaged by confocal microscopy using a 20× objective with 1 µm confocal sections that were
combined to give a projected thickness of 20 µm. Nerve density was measured as the area of TUBB3
immunofluorescent signal, as quantified using Tsai’s thresholding method (Moments) in ImageJ [38].
Integrated density was recorded with ImageJ. Total TUBB3 signal was normalized by the area of intact
epithelial tissue, labeled using Ecadherin, and expressed as normalized nerve density. Total IL6Ra
expression level was quantified using Tsai’s thresholding method, then normalized by the area of
the tissue.
Ductal cell proliferation was quantified by counting the number of Ki67+ cells in the NKCC1+
ductal cells. To obtain the percentage of proliferating cells per respective region, total cell counts were
divided by the number of NKCC1+ Hoechst-stained nuclei. Cell death was labeled using an antibody
directed against Cleaved Caspase 3 (CC3). Apoptosis was calculated by counting the number of CC3+
cells in the NKCC1+ ducts and dividing by the total number of NKCC1+ ductal cells to obtain the
percentage of apoptotic ductal cells. To obtain the percentage of acinar cell death, the number of CC3+
ECAD+ NKCC1- acinar cells was counted and divided by the total number of ECAD+NKCC1- cells.
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The result was used to quantitatively assess the loss of acinar cells and the expansion of the ductal cell
compartment. Lastly, the percentage of pSTAT3+ ductal cells was obtained by counting the number of
pSTAT3+ NKCC1+ cells and dividing by the total number of NKCC1+ ductal cells.
4.3. Western Blotting and Analysis
Tissues were lysed in radioimmunoprecipitation assay buffer (RIPA buffer) containing a cocktail
of protease inhibitors. Protein concentration was measured by bicinchoninic acid (BCA) assay (Thermo
Scientific, Waltham, MA, USA). A quantity of 10 µg of protein per samples was separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 4–12% Bis Tris gels (Invitrogen,
Carlsbad, CA, USA) and transferred to PVDF membranes. Membranes were blocked in 5% milk and
incubated in primary antibodies overnight at 4 ◦C: rabbit anti-Sema7a (1:500, Abcam, Cambridge,
MA, USA), Rabbit anti-Stat1 (1:1000, Cell Signaling), and mouse anti-Beta actin (1:1000, Sigma,
St. Louis, MO, USA). After washing three times in TBST, the blots were incubated with appropriate
horseradish-peroxidase-conjugated secondary antibodies and visualized with the Clarity Max Western
ECL chemiluminescence detection system (Biorad, Hercules, CA, USA). Densitometric quantification
of bands was performed using ImageJ software. To correct for sample-to-sample variability, the density
of the target protein band was normalized to the density of the loading control beta actin band,
for comparison of relative protein levels.
4.4. Lissamine Green Staining of the Ocular Surface
Five microliters of lissamine green dye (1%)were applied to the lower conjunctival cul-de-sac of
mice anesthetized with isoflurane, and images of the cornea were taken using an Olympus Zoom Stereo
Microscope (Olympus, Center Valley, PA, USA). Corneas were divided into four quadrants and scored
independently for the extent of staining in each quadrant. Scores were classified as Grade 0, no staining;
Grade 1, sporadic (<25%); Grade 2, diffuse punctate (25–75%), or Grade 3, coalesced punctate staining
(75% or more). The sum of the quadrants scored by three masked observers for each eye was calculated
on a scale ranging from 0 (no staining) to 12 (most severe staining) and plotted as the fold change
relative to the average WT score from the same age group.
4.5. Tear Secretion Measurement
Pilocarpine (4.5 mg/kg) was injected into the peritoneum (i.p), and after ten minutes, the mice
were anesthetized with isoflurane. Tear secretion was measured using a Zone-Quick phenol red thread
(Showa Yakuhin Kako Co. Ltd., Tokyo, Japan), to indicate mm of tears absorbed in 15 s.
4.6. RNA Isolation and RNAseq Analysis
Total RNA was collected and purified using RNAaqueous and DNase reagents according to the
manufacturer’s instructions (Ambion, Houston, TX, USA). For each RNA sample (RNA Integrity
Number (RIN) >6), cDNA libraries were prepared using the TruSeq mRNA library prep kit (Illumina
Inc, San Diego, CA, USA) using 1 µg RNA according to the manufacturer’s instructions and were
then 50 bp single-end sequenced on an Illumina HiSeq 4000. Quality control metrics were performed
on raw sequencing reads using the FASTQC v0.11.6 application [39]. Reads were mapped to the
Mus musculus genome (mm10 build) using Spliced Transcripts Alignment to a Reference (STAR) [17].
At least 90% of the reads were successfully mapped. Reads aligning to the University of California,
Santa Cruz (UCSC) mm10 build were quantified against Ensembl Transcripts release 93 using Partek®
E/M (Partek’s optimization of the expectation maximization algorithm, Partek Inc, St.Louis, MO, USA),
which disregarded any reads that aligned to more than one location or more than one gene at a single
location. Data was normalized by two procedures: 1. total count normalization, 2. addition of a small
offset (0.0001). After normalizing, differential gene expression was determined using the Differential
gene expression (GSA) algorithm (Partek). This algorithm generates p values using limma-trend
method 4. Genes were considered differentially expressed if the log2 Fold Change between samples
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was at least 1, with the adjusted p-value held to 0.01. Additionally, we considered only genes with
values of at least ten fragments per kilobase of transcript per million mapped reads (FPKM) in at
least one biological replicate. A gene list of all significantly modulated genes (p < 0.01) was used as
input for gene ontology (GO) analysis using Partek software. The resulting output was ranked by
adjusted p-value (Fisher’s exact test on the underlying contingency table). We consider an attribute to
be significant if its Expression Analysis Systematic Explorer (EASE) score (Fisher exact test p value)
is less than 0.05 relative to an appropriate background gene set. Gene sets were selected to highlight
unique features of the enrichment analysis. A principal component analysis (PCA) was performed on
normalized log2-transformed read counts using seven principal components. The dataset is available
on the GEO database.
4.7. Acetylcholinesterase Assay
To assess acinar cell function, the Amplex Red Acetylcholine/Acetylcholinesterase Assay Kit
(A12217) (Molecular Probes, Eugene, OR, USA), was used to measure acetylcholinesterase production
in three 20 µm fresh frozen OCT sections of the lacrimal gland.
4.8. Statistical Analysis
A minimum of three independent repeats were conducted in all experiments. Bar graphs are used
to summarize the means and standard errors of each outcome obtained using all data collected from
WT and Aire-/- mice. Data are presented as mean ± SEM. Student’s t-test was used for two-group
comparisons. One-way ANOVA was used for comparison across multiple groups; p ≤ 0.05 was
considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/11/
3628/s1.
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Appendix A
Table A1. Gene Ontology (GO) annotation enrichment for biological processes ranked by adjusted
p-values.
Gene Set Description Enrichment Score p-Value
GO:0002376 immune system process 122.222 8.32 × 10−54
GO:0045321 leukocyte activation 63.9325 1.72 × 10−28
GO:0046649 lymphocyte activation 50.3351 1.38 × 10−22
GO:0045087 innate immune response 38.6218 1.69 × 10−17
GO:0042110 T cell activation 31.974 1.30 × 10−14
GO:0002521 leukocyte differentiation 30.9403 3.65 × 10−14
GO:0032946 positive regulation of mononuclear cell proliferation 29.0482 2.42 × 10−13
GO:0006935 chemotaxis 28.0803 6.38 × 10−13
GO:0030098 lymphocyte differentiation 26.614 2.76 × 10−12
GO:0042113 B cell activation 25.1664 1.18 × 10−11
Int. J. Mol. Sci. 2018, 19, 3628 16 of 18
Table A1. Cont.
Gene Set Description Enrichment Score p-Value
GO:0010941 regulation of cell death 23.8593 4.35 × 10−11
GO:1902107 positive regulation of leukocyte differentiation 21.3797 5.19 × 10−10
GO:0032675 regulation of interleukin-6 production 18.6679 7.81 × 10−9
GO:0030890 positive regulation of B cell proliferation 18.5907 8.44 × 10−9
GO:0035458 cellular response to interferon-β 17.6558 2.15 × 10−8
GO:0042102 positive regulation of T cell proliferation 16.1908 9.30 × 10−8
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I 15.9125 1.23 × 10−7
GO:0050766 positive regulation of phagocytosis 15.7837 1.40 × 10−7
GO:0032755 positive regulation of interleukin-6 production 15.3477 2.16 × 10−7
GO:0034121 regulation of toll-like receptor signaling pathway 14.6507 4.34 × 10−7
GO:1901342 regulation of vasculature development 14.1787 6.95 × 10−7
GO:0048534 hematopoietic or lymphoid organ development 12.8039 2.75 × 10−6
GO:1904018 positive regulation of vasculature development 11.3609 1.16 × 10−5
GO:1904894 positive regulation of STAT cascade 10.2205 3.64 × 10−5
GO:0046427 positive regulation of JAK-STAT cascade 10.2205 3.64 × 10−5
GO:0042116 macrophage activation 9.6339 6.55 × 10−5
GO:0032663 regulation of interleukin-2 production 9.45996 7.79 × 10−5
GO:0032649 regulation of interferon-gamma production 9.51548 7.37 × 10−5
GO:0051092 positive regulation of NF-kappaB transcription factor activity 9.0688 0.00011521
GO:0032956 regulation of actin cytoskeleton organization 8.20972 0.000272
GO:0060333 interferon-gamma-mediated signaling pathway 8.15329 0.00028779
GO:0030101 natural killer cell activation 7.79743 0.00041079
GO:0071526 semaphorin-plexin signaling pathway 7.40996 0.00060519
GO:0002825 regulation of T-helper 1 type immune response 6.67123 0.00126683
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